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LGR5 Regulation of STAT3 Signaling and Drug Resistance in Colorectal Cancer
Tressie Alexandra Capri Posey B.S.
Advisory Professor: Kendra Carmon, Ph.D.
The greatest difficulty in treating colorectal cancer (CRC) is the development
of drug resistance which leads to relapse after treatment and progression to metastasis. Cancer
stem cells (CSCs) are believed to drive relapse because of their capacity to self-renew, acquire
resistance mechanisms, and differentiate promoting tumor growth and heterogeneity. Leucinerich repeat-containing G protein-coupled receptor 5 (LGR5), is a bona-fide marker of CSCs
and has been considered a viable target for CSC specific therapeutic development. While we
showed targeting LGR5 with antibody-drug conjugates (ADCs) led to tumor regression in
CRC xenografts, once treatment was ceased the tumor ultimately relapsed, possibly due to the
reemergence of LGR5+ CSCs. Recent studies have shown that LGR5+ CSCs undergo
plasticity converting from an LGR5+ state to a more chemo-resistant LGR5- state which can
lead to relapse. Recently, we reported that loss of LGR5 expression, through shRNA
knockdown (KD) or CRISPR knockout (KO) in multiple CRC cell lines, increased both
chemotherapy resistance and proliferation, however the complete mechanisms by which this
occurs is unknown. Through comprehensive western analysis, we discovered that loss of LGR5
expression increased phosphorylation of STAT3(Y705) and MET(Y1234/1235). Interestingly,
we also found that LGR5+ CRC cells treated with irinotecan or LGR5-targeted ADCs,
converted these cells to an LGR5- state with increased MET/STAT3 activation. LGR5
overexpression in a CRC cell line which doesn’t endogenously express LGR5, resulted in
decreased phosphorylation of MET/STAT3 and enhanced sensitivity to chemotherapy. We
next showed that LGR5- CRC cells are dependent on MET/STAT3 signaling for their acquired
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drug resistance and blockade of this pathway through chemical inhibition can be used to
enhance chemotherapy and ADC efficacy in vitro. Also, combination treatment with STAT3
inhibitor, stattic, and irinotecan in vivo resulted in increased tumor inhibition and survival
compared to either monotherapy alone. Our findings suggest that loss of LGR5 expression in
CRC cells promotes drug resistance, at least in part, through the activation of MET/STAT3
signaling and thus inhibition of STAT3 activity may restore drug sensitivity of LGR5- CRC
cells. Co-targeting LGR5+ CSCs along with molecular mechanisms that drive drug resistance
and cancer cell plasticity may be essential for a more effective CRC treatment.
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CHAPTER 1: INTRODUCTION
1.1 Colorectal Cancer (CRC) Disease Impact
Colorectal cancer (CRC) is the third most commonly diagnosed cancer and third most
common cause of cancer-related death globally, accounting for 10% and 9.4% respectively1.
In the United States alone, as of 2019 around 1.6 million men and women are currently living
with a history of CRC, an additional 150,000 diagnosed, and an estimated 50,000 patients
succumbed to the disease in 20202. With increasing incidence rates of CRC, the global burden
is expected to increase 60% over the next decade, culminating in more than 2.2 million new
cases and an estimated 1.1 million deaths by 20303.

Diagnosing CRC early is critical, as patients with early-stage diagnoses have an overall
5-year survival rate of up to 90%. However, the majority of CRC patients diagnosed with
advanced or later stage CRC only have an estimated 5-year survival rate between 10%-14%1,2.
While CRC surveillance through colonoscopy screening traditionally began at the age of 50,
the growing incidence rate among patients between the ages of 20-49 recently prompted the
U.S. Preventative Services Task Force to lower the age of initial screening to 45 in an effort to
improve outcomes through early detection4–6.

As late diagnosis is associated with advanced stages of CRC and poor prognosis, the
delay in non-urgent medical procedures due to the COVID-19 pandemic has many physicians,
patient advocates, and CRC researchers concerned. According to an early estimate, CRC
screenings have dropped by up to 86%; this delay in regular CRC screenings, especially in
medically underserved communities, could have a significant downstream impact on patient
outcomes7. While it cannot be determined how long it will take to return to pre-pandemic
1

screening levels or how great of an impact on public health this may cause, an increase in the
diagnosis of more advanced CRCs can be expected in time8.

1.2 CRC Progression and Treatment
While the majority of CRCs arise through sporadic appearance (70-80%), a small
portion is due to inherited genetic risk factors such as familial adenomatous polyposis (FAP),
Lynch Syndrome, or MYH-gene associated polyposis9. Once initiated, CRC develops through
a gradual, stepwise accumulation of genetic alterations which transform normal colonic
mucosa, to a polyp, which is followed by tumor progression, and eventually metastatic disease
(Fig. 1)10. This initial adenoma is most associated with mutations of Adenomatous Polyposis
Coli (APC), which can be inherited, as is seen in FAP, or acquired through somatic/sporadic
occurrence11. APC mutations lead to deregulation of the canonical Wnt/β-catenin signaling
pathway, resulting in enhanced transcription of target genes which causes an increase in cell
growth and proliferation11,12. After initiation through APC mutation, subsequent mutations
such KRAS and BRAF which act as oncogenic drivers continue to promote cellular expansion
of the tumor13. Eventually, mutations in PI3KCA, SMAD4, TP53, and other genes can arise,
generating malignant carcinoma behavior and leading to invasion and metastasis10,14. CRC can
also be classified into two major groups, microsatellite instability (MSI) where CRC cells are
hypermutated due to defective mismatch repair which accounts for ~16% of cases, or nonhypermutated microsatellite stable (MSS) which account for ~84% of cases. These factors can
have implication on adjuvant treatment decisions15.
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Figure 1: Adenoma to Carcinoma Sequence. Colorectal cancer progresses initially through the
formation of a benign adenoma brought on through sporadic or inherited oncogenic mutations,
primarily loss of functional APC. As the polyp develops, cells acquire aberrant mutations such as
KRAS, SMAD4, PTEN, and p53, gradually increasing in malignancy and developing into an
adenocarcinoma, followed by metastasis. (Adapted from “Benign and Malignant Colon Cancer”, by
BioRender.com (2021). Retrieved from https://app.biorender.com/biorender-templates)

CRC staging is classified by location and depth of invasion (T stage), presentation in
lymph nodes (N stage), and the presence of distal metastasis (M stage); staging is then used
for therapeutic decisions16. Based on the American Joint Committee on Cancer (AJCC): stage
1, CRC has not grown or invaded the inner mucosa layer of the colon nor has spread to the
neighboring lymph nodes; in stage 2, the tumor has grown into the outermost layer but may or
may not have grown through the mucosa layer; in stage 3, the cancer has grown through the
mucosa layer and has spread to nearby lymph nodes; and at stage 4, the cancer has spread to
at least one distant organ or other parts of the abdominal cavity17. The CRC adenomacarcinoma sequence can take between 10-15 years before neoplastic transformation leads to
the progression of invasive carcinoma18.
3

For stage 1-2 CRC, patients undergo surgical resection of the cancer and nearby lymph
nodes. Depending on how advanced the disease is, or if the tumor is obstructing function,
surgery is performed laparoscopically or through complete colonic resection. Surgery may also
be followed by adjuvant chemotherapy, however its use at such an early stage is considered
controversial19,20. In more advanced stage 2 or stage 3 CRC, surgery is still the primary form
of treatment, but it is performed with pre- and/or post-operative chemotherapy to reduce
incidences of local recurrence21,22. Conventional chemotherapy is based on 5-fluorouracil (5FU), given as a singular therapy or in combination with other chemotherapeutics23,24. 5-FU is
a variation of the metabolite uracil with a fluorine substitution for hydrogen at the carbon-5
position. Due to the tumor's preferential uptake of uracil for rapid generation of RNA, 5-FU
functions as an inhibitor of RNA transcription25. In combination, 5-FU is administered with
folinic acid (leucovorin, FOL) and either oxaliplatin (FOLFOX), which forms DNA adducts
through its platinum complex, or irinotecan (FOLFIRI), which inhibits topoisomerase 1 halting
replication and transcription, or both (FOLFOXFIRI)26,27. Because of the metastatic nature
invading of both lymph nodes and distant organs, stage 4 CRC is often considered incurable
with an average overall 5-year survival of 10-14%1,2,28. Stage 4 is treated with 5-FU
combination therapies (FOLFOX/FOLFIRI/FOLFOXFIRI), and more recently with the
inclusion of monoclonal antibodies (mAbs), such as Bevacizumab that directly targets vascular
endothelial growth factor (VEGF) and Cetuximab that targets epidermal growth factor receptor
(EGFR), which extend overall survival29,30.
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1.3 Challenges and Drug Resistance
The most prevalent obstacles in treating CRC is therapeutic resistance and relapse. In
fact, 30-40% of total patients develop recurrent disease, ranging from 5% in stage 1, to 60% in
stage 4, with around 70% of all recurrent disease observed within 2 years post-treatment2,3.
Recurrent disease often presents as distant metastasis occurring in the liver and lungs and with
increased malignancy31,32. This is due to nearly half of all metastatic CRC developing
resistance to 5-FU based chemotherapies, like FOLFIRI and FOLFOX, through multiple drug
resistant mechanisms33,34. Chemotherapy resistance has led to the inclusion of therapeutic
mAbs (i.e., Bevacizumab and Cetuximab) as treatment options to improve response rate35,36.
Unfortunately, the potential benefit of targeted therapy is only limited to a few months, as the
tumor can develop secondary resistance mechanisms to evade direct targeting of EGFR and
VEGF2,37,38. Furthermore, cetuximab has only shown to have potential benefit in the fraction
of CRC patients with wild-type KRAS and BRAF39. In addition, checkpoint inhibitor
immunotherapies (i.e., anti-CTLA4/PD1/PDL1), which have been proven to be effective
against other types of cancers, have only shown to be effective in a subset of microsatellite
instability-high (MSI-H)/mismatch repair deficient metastatic CRC patients (~16%), whereas
the remainder are microsatellite stable (MSS)39,40. In consequence, it is critical to develop new
therapeutics to improve the treatment of late-stage CRC.
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1.4 Colorectal Cancer Stem Cells
Drug resistance in CRC is closely related to its immense heterogeneity at both the
intertumoral and intratumoral levels. Tumors can be composed of a variety of different
molecularly defined subgroups which can determine therapeutic response41. Cancer stem cells
(CSCs) are a small sub-population within the tumor architecture that exhibit pluripotent stem
cell characteristics, able to self-renew and give rise to the different cancer cells which makeup the tumor. CSCs are also believed to drive drug resistance, tumor initiation, growth, and
likely play a role in relapse and metastasis (Fig. 2)42–44.

Figure 2: The Role of Cancer Stem Cells. Cancer stem cells (CSC) have the capability to
self-renew and generate differentiated daughter cells to initiate and maintain tumor outgrowth.
CSCs are also drug resistant to standard cancer therapies such as radiation and chemotherapy
(5-FU and irinotecan). CSCs also comprise a portion of circulating cancer cells which can
initiate metastatic outgrowth. (Adapted from “Stochastic vs Cancer Stem Cell Models”, by
BioRender.com (2021). Retrieved from https://app.biorender.com/biorender-templates.)
6

The traditional theory of how CSC arise depicts oncogenic mutations occuring in
normal adult stem cells resulting in tumor initiation. This theory presuming CSCs are the only
population with tumorigenic potential, however this linear progression has been directly
countered by the observation of mature cells de-differentiating into a stem-like state in order
to recapitulate the CSC population42,45,46. Once present, CSCs are capable of asymmetrically
dividing to produce identical daughter cells and differentiated tumor cells which are required
to maintain tumor growth45. CSCs and their progeny can contain a surprising amount of genetic
variability; they have been also shown to exhibit high expression of multiple drug resistant
proteins, proteins involved in DNA repair, and upregulation of signaling pathways which
promotes genetic variability leading to increased tumor heterogeneity47. CSC genetic
variability works in deadly combination with their slow cycling nature, evading standard
chemotherapies which tend to target rapidly proliferating cells46. This has led many researchers
to investigate possible CSC targeting therapies to eliminate the tumorigenic potential at its
source.

1.5 LGR5 as a Marker of Normal and Cancer Stem Cells
Leucine-rich repeat containing G protein-coupled receptor (LGR5) has been validated
as a marker for normal adult intestinal stem cells, expressed by the cycling crypt basal
columnar (CBC) stem cells restricted to the bottom of crypts in the gastrointestinal tract48,49.
These LGR5+ stem cells, asymmetrically divide and differentiate into all colonic epithelium
lineages and replenish the transit-amplifying region every 4-5 days49,50. LGR5 has also been
validated as a stem cell marker for normal adult stem cells within the liver, skin, stomach, and
ovarian epithelium51–54.
7

LGR5 is a bona fide marker for colorectal CSCs and is highly expressed in
approximately 60-70% of CRC 55–58. High LGR5 expression has been observed in every step
of the adenoma to carcinoma progression of CRC, including distant metastasis59,60. Despite its
high expression in CRC, there have been conflicting reports on its prognostic value. While
some correlation has been found with LGR5 expression and tumor progression, advanced
stage, and unfavorable prognosis; conflicting evidence have shown no true correlation with
tumor aggressiveness61–63.

1.6 LGR5 Function in Wnt Signaling and Interaction with IQGAP1
LGR5 is a seven transmembrane protein in the Rhodopsin-like family of G protein
coupled receptors (GPCR) with a large extracellular domain (ECD) that contains 17 leucinerich repeat sequences64. LGR5 has been established as a receptor for R-Spondin ligands,
(RSPO1-4), and shown to interact with the Wnt receptors Frizzled (Fzd) and Low-density
lipoprotein receptor-related protein 5/6 (LRP5/6). These proteins work concomitantly to
modulate Wnt/β-catenin signaling to dysregulate the destruction complex which is composed
of APC, Disheveled, Axin, CLIα, and GSK-3β, preventing this complex from marking βcatenin for degradation (Fig. 3)65–69. Along with being a modulator of the Wnt pathway, LGR5
is also a target gene for β-catenin transcription70. However, the complete mechanism and its
role in modulating Wnt/β-catenin, or other signaling pathways remains somewhat unclear.
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Figure 3: LGR5 modulates the Wnt Pathway. RSPO bound LGR5 interacts with Lrp5/6 and Wnt
bound Frizzled, the receptor complex inhibits the destruction complex, stabilizing β-catenin. Activated
β-catenin then translocates to the nucleus and engages in transcriptional activity. (Adapted from “Wnt
Signaling Pathway Activation and Inhibition”, by BioRender.com (2021). Retrieved from
https://app.biorender.com/biorender-templates)

Some findings suggest that the LGR5/RSPO complex promotes Wnt/β-catenin
signaling by sequestering E3 ubiquitin ligases Ring finger protein 43 (Rnf43), and Zinc and
Ring Finger 3 (ZNRF3), which negatively regulates Frizzled by inducing receptor
degradation70. Despite the substantial evidence for the interaction between the related receptor
LGR4 and RNF43/ZNFR3, there has been no direct evidence that RSPO-bound LGR5 directly
interacts with these E3 ubiquitin ligases71. RSPO bound LGR5 has been proven to interact with
Wnt receptors LRP6 and Fzd5, forming a signalosome, and is rapidly and constitutively
internalized in a Dynamin and Clathrin dependent manner. LGR5 likely stabilizes the coreceptors within the signalosome to potentiate Wnt/β-catenin signaling68,71,72. However,
9

LGR5’s role in Wnt activation may also be context dependent, as the silencing of LGR5 was
found to be associated with the increased activation of the Wnt pathway and upregulation of
several Wnt target genes73–75. This suggests that LGR5 may also play a suppressor role in Wnt
signaling.
Aside from modulation of canonical Wnt/β-catenin signaling, our lab showed that
LGR5 can play a role in altering the actin cytoskeleton structure to increase cell-cell adhesion,
independent of RSPO binding73. Our lab published findings that depict LGR5’s interaction
with the intracellular scaffold signaling protein IQ Motif Containing GTPase Activating
Protein 1 (IQGAP1). IQGAP1 has been shown to coordinate with various other receptors, such
as EGFR and MET, to regulate tumorigenesis, actin cytoskeleton dynamics, adhesion,
migration, and other cellular processes76–79. When bound to LGR5, IQGAP1 is
dephosphorylated leading to increased binding to Ras-related C3 botulinum toxin substrate 1
(Rac1)73. Once bound to Rac1, IQGAP1 is likely unable to interact with β-Catenin, leading to
increased E-cadherin-β-catenin-α-catenin complex formation and F-actin cross-linking and
ultimately stronger cell-cell adhesion80,81. This LGR5-IQGAP1 interaction posits an alternative
functional role for LGR5 by which it promotes the retention of normal stem cells within their
intestinal niche and strengthens the adhesion properties of colorectal CSCs.
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1.7 Therapeutic Targeting of LGR5+ CSCs
Since CSCs are able to evade chemotherapy and radiation, the direct targeting of CSC
markers has become a next step in improving the treatment of CRC82. Antibody-drug
conjugates (ADC) are mAbs which have been chemically linked to potent cytotoxic agents 83.
ADCs can be constructed to specifically target a tumor antigen, such as a CSC marker,
destroying tumor cells while circumventing damage to normal healthy tissues84. LGR5 has
been identified as an ideal candidate for ADC targeted therapy, due to its high expression in
CRC relative to low expression in healthy tissue and its rapid initialization which can shuttle
the ADC into CRC cells57,68. Our lab has previously generated two LGR5-targeting ADCs
linked with the antimitotic, tubulin-inhibiting agent monomethyl auristatin E (MMAE)57. One
ADC was composed of a chemical linker that could be cleaved by lysosomal enzymes to
release the drug into the cell, whereas the other ADC consisted of a non-cleavable linker which
was dependent upon proteolytic degradation for drug release57. It was found that in xenograft
mouse models of CRC that the ADC with the cleavable linker anti-LGR5-mc-vc-PAB-MMAE,
effectively eliminated high LGR5 expressing tumors57. In addition to our study, another group
demonstrated that ADCs targeting LGR5 suppressed LGR5+ tumor growth in xenografts and
genetically engineered mouse models and were also well tolerated85. However, our study
showed that tumors eventually reemerged when ADC treatment was ceased. This suggests that
a subpopulation of LGR5+ CSCs may have interconverted to an LGR5- with a resistant
phenotype that was able to eventually re-initiate tumor growth, this process of interconversion
is known as stem cell plasticity57.
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1.8 LGR5+ CSC Plasticity in Treatment and Progression
While the traditional CSC model depicts a small subpopulation of self-renewing
quiescent cells which are likely responsible for tumor initiation and maintaining tumor growth,
this does not account for the reemergence of stem cells after treatment with CSC-targeted
therapy. These observations propose that daughter stem cells, including those that have
differentiated, may de-differentiate in order to maintain tumor by replenishing the stem cell
population86,87. This process is referred to as cell plasticity and has been observed in healthy
intestinal tissue where committed progenitors of both secretory and enterocyte lineages take
on a pluripotent phenotype to reconstitute lost LGR5+ CBCs after damage; this same
phenomenon is believed to occur in CRC88,89.
In fact, CSC plasticity has been demonstrated in xenograft models of human CRC, as
selective ablation of LGR5+ CSCs restricted primary tumor growth but failed at tumor
regression. The LGR5- CRC cells proliferating and maintaining the tumor, were shown to
eventually replenish the LGR5+ CSC pool leading to rapid re-initiation of tumor growth 43,90.
LGR5+ CSCs have also been shown to interconvert to an LGR5- state in response to both
chemo- and radio- therapy, and once treatment was ceased, these cells regained LGR5
expression91,92. LGR5- CRC cells still maintained a number of other stem cell markers and
were shown to have increased drug resistance to 5-FU, oxaliplatin, irinotecan and were also
more radio resistant. Additionally, our group showed that shRNA knockdown or CRISPR
knockout of LGR5 in CRC cells promoted a more chemo-resistant phenotype93. As mentioned
previously, we observed cancer cell plasticity by selective targeting of LGR5+ CRC cells with
our anti-LGR5 ADC, which did lead to tumor size regression, yet LGR5-low/negative tumors
re-emerged in a fraction of the mice once treatment was ceased57.
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Loss of LGR5 along with CRC plasticity may potentially be an important step in
metastatic progression of CRC. A recent study by Fumagalli et. al. demonstrated that not only
were the majority of disseminated CRC cells in circulation lacking LGR5 expression, but these
LGR5- cells were also responsible for seeding and initiation of metastases94. Once seeded the
LGR5- CRC cells reacquired LGR5 expression which drove proliferation and metastatic
outgrowth90,94. This suggests that co-targeting LGR5 along with the molecular mechanism(s)
that drive CRC plasticity or drug resistance may be essential to successfully treat CRC and
prevent progression and relapse.

1.9 STAT3 activation
Signal transducer and activator of transcription 3 (STAT3) is one of seven in the STAT
protein family, this family of proteins act as both cytoplasmic signaling proteins and nuclear
transcription factors for gene activation95. STAT proteins receive and transmit cytoplasmic
signaling from tyrosine-kinase receptor activated by either cytokines or growth factors95,96.
Once STAT3 is activated by phosphorylation on critical tyrosine residues (i.e., Tyr 705),
phosphorylated STAT3 dimerizes head-to-tail and translocates to the nucleus (Fig. 4)97.
Dimerized STAT3 is trafficked to the perinuclear compartment by a signalosome, ensuring
efficient nuclear accumulation98. Once in the nucleus, STAT3 binds to a promoter region and
activates transcription of a number of target genes involved in cellular proliferation (e.g. Cyclin
D1), survival (e.g. Bcl-xL), differentiation, and cancer stem cell expansion99. STAT3 has been
shown to be one of the most important STAT proteins in cancer and its progression, this is due
to the overexpression of a number of its upstream modulators such as Interleukin-6 receptor
(IL-6R), EGFR, and/or c-MET.
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Figure 4: STAT3 Activation by Cytokine or Growth Factor Receptors. A variety of cell membrane
receptors, such as interleukin-6 receptor (IL-6R), Epidermal Growth Factor Receptor (EGFR) and
HGF/Scatter Factor Receptor (MET) activate Signal Transducer and Activator of Transcription 3
(STAT3) mediated through Janus-Kinase (JAK). Phosphorylated STAT3 dimerizes resulting in
translocation to the nucleus where it binds to the promoter region to induce transcription of various
genes that mediate cellular processes. (Adapted from “Cytokine Signaling through the JAK-STAT
Pathway”, by BioRender.com (2021). Retrieved from https://app.biorender.com/biorender-templates)

The IL-6/Janus kinase (JAK)/ STAT3 pathway is believed to be a key component in
CRC tumorigenesis as IL-6 production has been found elevated in both CRC tissue and patient
serum100. When IL-6 binds to IL-6R it complexes with Glycoprotein 130 (Gp130), which
subsequently phosphorylates JAK leading to STAT3 activation through phosphorylation at its
tyrosine 705 position101. While Gp130 is ubiquitously expressed in most cells, IL-6R is
exclusively expressed in certain cells such as hepatocytes and leukocytes restricting signaling.
However, a soluble form of IL-6R exists which can circulate and interact with Gp130 allowing
IL-6 to broaden its target cells including epithelial cells to enhance signaling102.
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EGFR is another upstream activator of STAT3 with aberrant expression in CRC cancer
and is currently a therapeutic target in late-stage CRC103,104. EGFR is a transmembrane receptor
tyrosine kinase which is primarily responsible for the activation of mitogen activated protein
kinase (MAPK) pathway. MAPK triggers multiple phosphorylation cascades such as the RasRaf-Mek-Erk activation and dysregulation of this pathway leads to malignant transformation,
tumor progression, proliferation, along with invasion and metastasis13,105. In addition to
activating MAPK, EGFR has been shown to activate STAT3 through the phosphorylation of
JAK or through direct phosphorylation of STAT3106.
Hepatocyte growth factor/scatter factor (HGF) and its receptor (HGFR) or
(mesenchymal epithelial transition receptor) MET also participates in the activation of STAT3.
Like EGFR, MET is a transmembrane tyrosine kinase receptor which is overexpressed in CRC
and associated with worse survival outcomes107. MET expression has been shown to
progressively increase with the development and progression of CRC and is especially high in
distal metastasis108–110. Once bound, HGF dimerizes MET leading to autophosphorylation of
its tyrosine residues which act as a docking site for multiple substrates including STAT3111.
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1.10 STAT3 function in CRC and CSCs
STAT3 expression has been shown to be significantly associated with higher mortality
in CRC and its increased expression in both the cytoplasm and nucleus have been shown to
correlated with depth of tumor invasion and staging112,113. Its expression has also been
associated with CRC initiation and progression with its over activation enhancing cancer cell
proliferation, tumor growth, invasion, migration, and survival114,115. Increased STAT3 over
activation and expression in CRC has also been correlated with CRC resistance to 5-FU based
chemotherapy and radiation therapy. STAT3 expression is also implicated in resistance to antiEGFR therapy, as its phosphorylation levels in metastatic CRC was increased in patients that
had a poor response to EGFR targeted therapy116–118.
STAT3 signaling was also found to be highly active in CSCs, playing an important role
in CSC persistence during and after treatment by stimulating transcription of genes involved
in cell cycle progression, DNA synthesis, replication, and repair119. In addition to CSC
maintenance, STAT3 is also an important player in epithelial-mesenchymal transition (EMT),
a process where epithelial cells acquire mesenchymal phenotypes. EMT has been strongly
linked to cancer cell plasticity, as many of its markers have been found to be associated with
the acquisition of CSC properties120. Inhibition of STAT3 through small molecule inhibitors
has been shown to sensitize cancer cells to chemotherapy in CRC and is considered a potential
drug target for CRC121.
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1.11 Project Goal
The goal of this study was to identify a possible targets or mechanisms that are
upregulated due to the loss of LGR5 and which are also associated with CRC plasticity and
drug resistance. We hypothesize that loss of LGR5 expression in CRC cells promotes drug
resistance through activation of STAT3, and thus, inhibition of STAT3 activity may potentially
restore drug sensitivity of LGR5-low/negative cells. Our specific aims are: (1) to characterize
the effect of LGR5 expression in the regulation of STAT3 signaling, (2) examine the role of
LGR5 and STAT3 in drug resistance and CRC cell plasticity in vitro, and (3) determine if
STAT3 inhibition enhances drug sensitivity of CRC tumors in vivo. This project may lead to
the identification of novel molecular mechanisms that mediate drug resistance and CRC cell
plasticity. Co-targeting of LGR5 and these molecular mechanisms may be essential for the
improved treatment of CRC.
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Chapter 2: Materials and Methods

2.1 Antibodies, Plasmids, and Chemicals
The primary antibodies MET (#8198), STAT3 (#9139), β-Catenin (#8480), EGFR
(#4267), JAK (#3230), ERK 1/2 (#4695), MEK 1/2 (#9122), BIM (#2933), Bcl-XL (#2764),
Cyclin D1 (#2922), Axin 2 (#2151), SHP-2 (#3397), and β-Actin (#3700), p-MET Y1234/1235
(#3077), p-STAT3 Y705 (#9145), p-STAT3 Y727 (#9134), Non-p-β-Catenin (#8814), pEGFR Y1068 (#4407), p-EGFR Y992 (#2235), p-JAK (#3776), p-ERK 1/2 T202/Y204
(#9101), p-MEK 1/2 S217/221 (#9121), p-SHP-2 Y580 (#3703), p-SHP-2 Y542 (#3751) were
purchased from Cell Signaling Technology. The primary antibodies for LGR5 and p-EGFR
Y1173 were purchased from Abcam, and the primary antibody for IQGAP1 was purchased
from Bethyl Laboratories. Secondary antibodies anti-rabbit IgG, HRP-linked (#7074) and antimouse IgG, HRP-linked (#7076) were also purchased from Cell Signaling. For
immunocytochemistry TO-PRO-3 (Thermo Fischer Scientific) was used for nuclear staining,
and secondary antibodies goat-anti-mouse-Alexa-488, goat-anti-rabbit-Alexa 488, and goatanti-human-Alexa 555 were purchased from Invitrogen. The LGR5 (8F2) mAb and cleavable
anti-LGR5-MMAE (anti-LGR5-mc-vc-PAB-MMAE) ADC were generated previously as
described and contained a drug-to-antibody ratio of 457. The plasmids encoding myc-LGR5
was generated previously66. Constitutively active mouse STAT3 (STAT3-CA) plasmid Stat3C Flag pRc/CMV was a gift from Jim Darnell (Addgene plasmid 8722).
Chemotherapies, irinotecan hydrochloride and irinotecan hydrochloride trihydrate
were purchased from Selleck Chemical and 5-fluorouracil (5-FU) was purchased from Acros
Organics. The STAT3 inhibitors, stattic and cryptotanshinone (Crypto), and the EGFR
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inhibitor Gefitinib were also purchased from Selleck Chemical. The MET inhibitor, crizotinib
was purchased from Cell Signaling, GP130 inhibitor SC144 was purchased from Millipore,
and the β-catenin inhibitor XAV939 was purchased from Cayman Chemical. Therapeutics
used for in vitro experiments were resuspended in Dimethyl Sulfoxide (DMSO, Fisher). For in
vivo experiments, stock irinotecan hydrochloride was resuspended in 10% DMSO and 5%
sterile dextrose in water (D5W, Fisher Bioreagents), stock stattic was resuspended in 10%
DMSO, 35% polyethylene glycol 300 (PEG-6: Fisher Bioreagents), 5% Tween 80 (Spectrum),
and D5W.

2.2 Cell Culture, Stable Cell Lines, and Transfection
HEK293T, DLD-1, HT-29, and HCT116 cells were purchased and authenticated by
ATCC. LoVo cells were provided by the laboratory of Dr. Shao-Cong Sun (MD Anderson
Cancer Center, Houston TX). HEK293T and HCT116 cells were grown in Dulbecco modified
Eagle medium (DMEM; Gibco), HCT 116, DLD-1, LoVo and LS180 cells were grown in
Roswell Park Memorial Institute medium (RPMI; Gibco). All media was supplemented with
10% fetal bovine serum (FBS) and penicillin /streptomycin (Gibco). Cells were incubated at
37°C with 95% humidity and 5% CO2. To generate stable cell lines with altered LGR5
expression, LoVo and DLD-1 were infected with lentiviral particles containing shRNA
targeting human LGR5 as previously described73. Briefly, lentiviral particles were generated
through the co-transfection of HEK293T cells with pLKO.1 vector containing the shRNA
TRCN0000011586 (shLGR5-1) or TRCN0000011589 (shLGR5-2) (GE Dharmacon) and
packing plasmids, psPAX2 and pMD2.G using Fugene 6 (Roche, Basel, Switzerland). Cells
were infected and selected in the presence of 1µg/mL puromycin (Life Technologies) or 200
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ng/mL G418 (Corning). In LS180, LGR5 was knocked out using a Lenti-CRISPRv2 vector
system with the guiding sequence CAG GAG CAC ACC GAG CCG GG, which targeted
nucleotides 314-295 in the open reading frame of human LGR5 as described93. Transient
transfections were performed using jetPRIME (Polypus Transfection).

2.3 Western Blotting
For western blot analysis, cells were harvested with either radio-immunoprecipitation
assay (RIPA) buffer; (50 mm Tris-Cl, pH 7.4, 150 mm NaCl, 1 mm DTT, 1% Triton X-100,
1% sodium deoxycholate, and 0.1% SDS) or in immunoprecipitation lysis (IP) buffer; (25 mm
Tris-HCl, pH 7.4, 150 mm NaCl, 1 mm EDTA, 1% Nonidet P-40, and 5% glycerol)
supplemented with protease and phosphatase inhibitors. Lysates were then subjected to
sonication and centrifuged at 13,000g for 10 minutes and supernatants were mixed with 1X
Laemmli sample buffer (Bio-Rad). Samples were incubated at 37°C for 45 minutes then loaded
on to SDS-PAGE 20 gel (Invitrogen) with XCell4 Surelock Midi-Cell (Invitrogen) at 120 V
for 120 minutes in 1X Tris-Glycine SDS running buffer (Fisher Scientific). Protein gels were
then transferred to nitrocellulose blotting membrane (Amersham by GE Healthcare Life
Sciences) at 400 amps for 120 minutes on ice with Criterion Blotter (Bio-Rad) in 1X TrisGlycine transfer buffer (Fisher Scientific) with 20% methanol. Blots were incubated with
indicated primary antibodies in 2.5% non-fat milk (Research Products International) in trisbuffered saline solution (Fisher Scientific) with 1% Tween 20 (TBST, Fisher Bioregents).
After primary antibodies were washed from the blots using TBST, HRP-labeled secondary
antibodies were added in 2.5% milk TBST solution, then washed again with TBST. Proteins
were detected using the standard protocols for Enhanced Chemiluminescence (ECL) purchased
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from either Cytiva or KwikQuant. Western blots were exposed by x-ray film or camera imager
(KwikQuant).

2.4 Immunocytochemistry and Confocal Microscopy
For immunocytochemistry (ICC) experiments, LoVo, DLD1, or LS180 cells were
seeded into an 8-well poly-D-lysine coated chamber slides and allowed to adhere overnight.
The following day cells were treated with or without chemotherapies as indicated. Of note,
irinotecan hydrochloride trihydrate was used for ICC as it produced less autofluorescence than
irinotecan hydrochloride. Cells were washed with PBS, fixed with 4% (vol/vol)
paraformaldehyde solution for 15 minutes and permeabilized with 0.3% 1X Triton-X (Life
Technologies) or 0.1% saponin (Sigma) for 10 minutes. Cells incubated at room temperature
with primary antibody for 1 hour and treated with anti-rabbit-Alexa-488, anti-mouse-Alexa488, or anti-human-Alexa-555 at room temp for 1 hour. For internalization studies, cells were
incubated with anti-LGR5 mAbs at 37°C for 30 minutes prior to fixation. Nuclei were
counterstained with TO-PRO-3) at room temperature for 5 minutes. Slides were mounted with
ProLong™ Gold Antifade Mountant (ThermoFisher) and images were acquired by confocal
microscopy (Leica TCS SP5 microscope) and analyzed with LAS AF Lite software (Leica
Microsystems, Inc).
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2.5 Wound Healing Assay
For wound healing assays LoVo and DLD1 cells were seeded to near confluence in 12well plates and then starved in either 1% FBS or serum free-media overnight. The following
day cells were scratched with a 200uL pipette tip, cells were then washed with PBS to remove
cellular debris. Wells were then refreshed with starve media along with the respective
treatment. The wound was then subsequently imaged at 0, 24, and 48 hours and wound closure
was evaluated through ImageJ.

2.6 Cell Invasion Assay
For invasion assays, 8-µm pore Transwell migration chambers (BD Bioscience) were
coated with a 1:40 mixture of BD BioCoat Matrigel: serum-free RPMI media and allowed to
solidify. Cells (5 x 104) were then seeded into the top chamber and allowed to invade at 37°C
for 48 hours towards the bottom chamber containing RPMI with 10% FBS. Cells were fixed
in 4% paraformaldehyde for 10 minutes, washed with PBS, and then permeated with 100%
methanol for 10 minutes before being stained with 0.005% crystal violet (Sigma) solution and
rinsed in water. A cotton swab was then used to gently remove any remaining non-invasive
cells and rinsed again. Stained cells were examined through light microscopy and 5 individual
fields were imaged and quantification (i.e., percent invasion) was determined using ImageJ.
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2.7 Clonogenicity
Clonogenicity was analyzed by seeding 5 X 103 cells into a 6-well culture plate with
and allowed to adhere overnight. Cells were then treated with or without therapeutics as
indicated and cultured for 7 days, refreshing media and treatment on day 3. After growth, cells
were washed with PBS before being fixed with 4% paraformaldehyde and stained with 0.005%
crystal violet and rinsed with sterile water. Stained cell colonies were then imaged and colony
count and percent well coverage were analyzed using ImageJ.

2.8 In Vitro Cytotoxicity
For cytotoxicity analysis, cells were seeded at 1.5-2 x 103 per well in a white 96 halfwell plate (Corning). Plated cells were then treated with serial dilutions of specified therapeutic
compounds or ant-LGR5-MMAE ADC then incubated at 37°C for 3-4 days. Cytotoxicity was
then quantified using the CellTiter-Glo (Promega) Luminescent Cell Viability Assay and
Envision multilabel plate reader (PerkinElmer).

2.9 In Vivo studies
Animal studies were performed in line with the strict recommendations of the Institutional
Animal Care and Use Committee of the University of Texas Health and Science Center at
Houston (AWC-20-0144)). Female nu/nu mice between 6-8 weeks old (Jackson Laboratory)
were subcutaneously inoculated into the lower right flank with 1 x 106 LoVo cells in PBS.
Once tumors reached an average size of ~100 mm3, animals were randomized into four
treatment groups (vehicle, stattic, irinotecan, or irinotecan + stattic). Irinotecan (20 mg/kg) or
vehicle (2% DMSO in D5W) was administered intraperitoneally every five days for three
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doses. Stattic (10mg/kg) or vehicle (4% DMSO, 14% PEG300, and 2%Tween in D5W) was
administered intraperitoneally every other day for a total of six doses. Tumor volume was
measured every 2 days and calculated using the formula: Tumor Volume = (Length x width2)/2.
Mice were euthanized when tumor volume reached approximately 2000 mm3.

2.10 Statistical Analysis
Statistical analysis was performed and IC50s determined using the Prism 5 (GraphPad
Software, Inc.). All in vitro experiments were performed at least three times. The levels of
significance between samples were determined through an unpaired two-tailed Student t test
(mean comparison with one factor) or one-way ANOVA for groups with multiple comparisons.
Data are shown as mean ± standard error of the mean (SEM) or standard deviation (SD) as
indicated, with P values ≤ 0.05 considered to be statistically significant.
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Chapter 3: Results

3.1 Chemotherapy and ADC treatment of CRC cell lines decreases LGR5
expression
To test if LGR5+ CRC cells convert to an LGR5- state during drug treatment, we
measured changes in LGR5 expression in response to different chemotherapeutics. CRC cell
lines LoVo, DLD1, and LS180 were selected based on for their high expression of LGR5. As
we previously published, LoVo cells contain the highest level of LGR5 protein expression as
confirmed by western blot and gene expression as indicated by data obtained from the Cancer
Cell Line Encyclopedia (CCLE)57. CRC cells were treated with 10µM of either 5-FU or
irinotecan at indicated time-points; LGR5 expression was then detected by western blot
analysis (Figs. 5A-B). LGR5 expression was nearly undetectable after 72 hours of
chemotherapy treatment in LoVo and LS180 cells and was found decreased in DLD1 cells
(Figs. 5A-B). Loss of LGR5 expression was confirmed through ICC staining, demonstrating a
gradual decrease in LGR5 expression at 24 hours and complete loss at 72 hours (Fig. 5C).
To test if CRC cells were entering a similar LGR5- state with targeted therapy, LoVo
and LS180 cells were treated with 1µg/mL of anti-LGR5-MMAE ADC at indicated time
points. This dose was selected as previous experiments showed it did not result in complete
cell death after 72 hours57. Like chemotherapy treatment, LGR5 expression was undetectable
at 72 hours in LoVo cells and 48 hours in LS180 cells (Fig. 5D). To demonstrate plasticity and
determine if LGR5- CRC cells can convert back to an LGR5+ state, LoVo and LS180 were
treated with either irinotecan or anti-LGR5-MMAE ADC for 72 hours and cells were either
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harvested or washed and allowed to recover for an additional 72 hours. We show that after
treatment was ceased, and drug was removed, LGR5 expression re-emerged, providing
evidence of CRC cell plasticity (Fig. 5E). Furthermore, this data suggests that the LGR5- state
which these cells enter may be more drug resistant with activated survival mechanisms.

Figure 5. Drug Treatment leads to loss of LGR5 expression. (A-B) LoVo and LS180 CRC cells
were treated with 10µM of either (A) irinotecan or (B) 5-FU for 0, 8, 24, and 72 hours. LGR5 expression
was detected by western blot. (C) Confocal microscopy images of LGR5 expression in LoVo and
LS180 after treatment of 10µM of irinotecan for 0, 24, and 72 hours. (D) LoVo and LS180 cells were
treated with 1µg/mL of anti-LGR5-MMAE ADC for 0, 24, 48, and 72 hours and LGR5 expression was
detected by western blot. (E) CRC PDX organoids were treated with 10µM irinotecan or 1µg/mL antiLGR5-MMAE ADC for 3 days and LGR5 expression was detected by western blot. (F) LoVo and
LS180 were treated with vehicle, anti-LGR5-MMAE ADC, or irinotecan for 72 hours, washed with
PBS, and allowed to recover for 3 days. LGR5 expression was detected by western blot.
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3.2 Loss of LGR5 leads to increased survival and invasive phenotype
In a recent publication, our lab generated LGR5 KD LoVo and DLD-1 cell lines using
shRNA constructs and LGR5 CRISPR/Cas9 KO LS180 cell lines93. We showed that LGR5KD
or KO enhanced resistance to both 5-FU and irinotecan supporting the hypothesis that loss of
LGR5 conferred a more drug resistant state93. Given these findings, we performed survival
assays in vitro to test changes in clonogenicity. As shown in Figs. 6A-B, LoVo cells with
LGR5KD (shLGR5-1 and shLGR5-2) had around a 3-fold increase in colony formation
compared to parental and vector (shCTL) control cells, and an approximate 3-6-fold and 10fold increase in the presence of 5-FU and irinotecan, respectively (Figs. 6A-B). Next, we
evaluated the effect of loss of LGR5 on migration and invasion, which are critical for CRC
progression and metastasis. Using wound heal assays, we found that both LoVo LGR5KD cell
lines exhibited a 3-4-fold (15-20%) increase in percent wound closure compared to parental
and shCTL (5%) (Figs. 6C-D). In the presence of 10µM irinotecan, LGR5KD cells showed an
increase in wound closure compared to parental and shCTL cells. Parental and shCTL cells
showed a decrease in closure in the presence of irinotecan compared to untreated, likely due
to a decrease in cell viability (Figs. 6C-D). Next, we tested effects of loss of LGR5 on cell
invasion. We found LGR5KD in LoVo cells increased invasion by 3-4-fold (Fig. 6E). Taken
together, loss of LGR5 not only leads to drug resistance but also potentially induces a more
metastatic phenotype.
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Figure 6. Effect of LGR5 knockdown on CRC cell function. (A-B) Clonogenicity assay of LoVo
cells treated with or without 10µM irinotecan or 5-FU and incubated for 7 days, cells were then stained
with crystal violet. (A) Quantification of clonogenicity assay and (B) representative images of colonies
stained with crystal violet. (C) Quantification of wound healing assay and (D) representative images of
wound healing assay. (E) Quantification of invasion assay. Data represent mean +/- S.E.M. of at least
three experiments. Statistical analysis was performed using one-way ANOVA, *, P ≤ 0.05, **, P ≤
0.01, ***, P ≤ 0.001 compared to controls.
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3.3 LGR5 knockdown CRC cells have increased STAT3/MET phosphorylation
To identify signaling mechanisms that may mediate plasticity and drug resistance in
LGR5- CRC cells, we performed a western blot analysis to determine changes in protein
expression. In LoVo cells, LGR5KD resulted in increased its non-phosphorylation of active βcatenin (as we previously reported)93, JAK (Y1007/1008), and STAT3 (Y705) (Fig. 7A).
Along with increased STAT3 nuclear accumulation we also observed alteration in the
expression of STAT3-associated survival proteins that prevent cell cycling arrest and
apoptosis. Specifically, loss of LGR5 lead to increased Bcl-xL and Cyclin D and decreased
BIM expression (Fig. 7B). These results suggest that loss of LGR5 increases both Wnt and
STAT3 activation in CRC cells. Through ICC and confocal analysis, we observed that loss of
LGR5 through shRNA KD in LoVo cells leads to increased nuclear accumulation of β-catenin
and phosphorylated STAT3 indicating increased Wnt and STAT3 signaling (Fig 7C).
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Figure 7. Loss of LGR5 increases phosphorylation of STAT3 and MET. (A) Western blot analysis
of changes in protein levels and phosphorylation in LoVo cells with or without LGR5 KD. (B) Western
blot of changes in expression of STAT3-associated survival proteins. (C) Confocal microscopy images
of STAT3 phosphorylation and activate β-Catenin in LoVo cell lines.
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3.4 IL-6R/Gp130 and EGFR pathways do not mediate STAT3 activation in
LGR5KD cells.
To identify which upstream mediators may be responsible for increased STAT3
activation, we chemically targeted three cell membrane receptors, IL6/Gp130, EGFR, and
MET which are known to specifically phosphorylate STAT3 (Y705). IL6/Gp130 activation
has been correlated with CRC disease status and metastasis and is most associated with the
activation of STAT3. However, most commercial CRC cell lines do not express high levels of
IL6R, which was confirmed for LoVo cells by the CCLE database. We also failed to detect
IL6R by western blot in LoVo cells (not shown). To observe if Gp130 activation is playing a
role in STAT3 activation, LGR5KD LoVo cells were treated with 10µM of Sc144, a small
molecule Gp130 inhibitor, at indicated times. It was found that inhibition Gp130 did not
suppress STAT3 activation (Fig. 8A). Therefore, it is likely that IL6R/Gp130 receptors are not
responsible for the altered STAT3 signaling.
As mentioned previously, EGFR is often targeted in late-stage CRC and is involved in
progression and survival, both of which mediate its activation of several downstream signaling
factors like MAPK and STAT3. Through western analysis, no significant increase in EGFR
phosphorylation at sites, Y1068, or Y1173 were observed in LGR5KD LoVo cells (Fig. 8B).
LGR5 KD LoVo cells treated with 10 µM gefitinib, an EGFR inhibitor at indicated times,
showed no significant decrease in STAT3 activation (Fig. 8C). These findings suggest that
STAT3 activation is most likely not mediated through EGFR activation.
Since loss of LGR5 also leads to increased levels of active β-catenin, we tested if
increased phosphorylation of STAT3 was potentially mediated through Wnt signaling.
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LGR5KD LoVo cells were treated with 10 µM XAV939, a tankyrase inhibitor that stimulates
β-catenin degradation by stabilizing Axin, at indicated times. XAV939 showed increased
stabilization of Axin2, however no significant decrease in STAT3 activation was detected (Fig.
8D). These findings suggest that STAT3 activation is likely not mediated through β-catenin
activation.

Figure 8. Inhibition of IL6R/Gp130 nor EGFR attenuated STAT3 activation in LGR5 KD cells.
(A) Western blot analysis of STAT3 in LoVo cells treated with 10µM Sc144 for 0, 1, and 2 hours. (B)
Western blot of EGFR phosphorylation in LoVo cells. (C) Western blot analysis of STAT3 and EGFR
and STAT3 phosphorylation in LoVo LGR5 KD cells treated with 10µM gefitinib for 0, 6, and 24
hours. (D) Western blot analysis of STAT3 phosphorylation and Axin2 expression in LoVo LGR5 KD
cells treated with 10µM XAV939 for 0, 6, and 24 hours.
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3.5 STAT3 activation is mediated through MET Signaling.
Next, to verify if MET plays a role in STAT3 activation we analyzed changes in MET
phosphorylation and expression in LoVo cells. We observed an increase in both the mature
form of MET and phosphorylation of MET (Y1234/1235). We also detected increased MET
and STAT3 phosphorylation in DLD-1 LGR5KD cells and LS180 LGR5KO (1.4 and 1.5) cells
(Figs 9A-C). We also found an increase in cytoplasmic and nuclear presence of phosphorylated
MET through ICC (Fig. 9D). The effect of MET inhibition on STAT3 was investigated by
treating LGR5KD cells with the MET inhibitor crizotinib. We observed by western blot
analysis that after 6 hours of treatment there was a complete loss of phosphorylated STAT3
(Fig. 9E). This suggests that STAT3 activation is mediated through activation of MET. In turn,
we also observed loss of phosphorylated MET after treating cells with STAT3 inhibitors
cryptotanshinone (Crypto) and stattic (Fig. 9E). This suggests that in LGR5KD cells, enhanced
MET/STAT3 signaling may rely on a potential positive feedback loop between MET and
STAT3 to drive survival and drug resistance.
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Figure 9. MET mediates STAT3 activation through a potential positive feedback loop. (A)
Western blot analysis of changes in MET phosphorylation in LoVo cells with or without LGR5 KD.
(B-C) Western blot of changes in phosphorylation of STAT3 and MET in (B) DLD1 with or without
LGR5 KD and (C) LS180 parental or LGR5 KO clonal cells lines 1.4 and 1.5. (D) Confocal
microscopy images of phosphorylated and total MET in LoVo cell lines. (E) Western blot analysis
of changes in MET and STAT3 phosphorylation in LoVo LGR5 KD cells treated with 10 µM
crizotinib, cryptotanshinone, or stattic at indicated time-points.
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3.6 Chemotherapy and ADC treatment of CRC cell lines increases
MET/STAT3 activation
Since treatment with irinotecan or anti-LGR5-MMAE ADC was shown to convert
LGR5+ CRC cells to an LGR5- state (Fig. 1), we tested if levels of MET and STAT3 were
also changed. As shown in Fig. 10A-B, increased MET and with STAT3 activation was
detected in LoVo and LS180 cells treated with 10 µM irinotecan. CRC cells treated with 1
µg/mL anti-LGR5-MMAE ADC also led to increased phosphorylation of MET and STAT3
(Fig. 10C-D). These findings show that drug-induced loss of LGR5 in CRC cells leads to
activation of MET/STAT3 in a manner similar to LGR5KD or KO.
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Figure 10. Drug treatment leads to increased Met/STAT3 signaling with loss of LGR5. (A-B)
Western blot analysis of MET and STAT3 phosphorylation in (A) LoVo and (B) LS180 cells treated
with irinotecan at different time-points. (C-D) Western blot analysis of MET and STAT3
phosphorylation in (C) LoVo and (DB) LS180 cells treated with anti-LGR5-MMAE ADC at different
time-points.
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3.7 MET/STAT3 activation mediates drug resistance in LGR5 KD cells
To determine if LGRKD cells dependent on MET/STAT3 activation, we tested the
impact of MET and STAT3 inhibitors on cell viability. We found that LGR5KD LoVo and
LGR5KO LS180 cells were more sensitive to the MET inhibitor and STAT3 inhibitors stattic,
and cryptotanshinone (Fig. 11A-F). The IC50s were approximately 4 to 8-fold and 1.5 to 6fold lower for LoVo LGR5KD and LS180 LGR5KOs compared to control cell lines,
respectively (Fig. 11G). This suggests that MET/STAT3 activation may be integral for the
survival of LGR5KD cells.
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Figure 11. LGR5 knockdown and knockout cells are more sensitive to inhibitors of MET and
STAT3. (A-B) Cytotoxicity assays of (A) LoVo and (B) LS180 cells treated with MET inhibitor,
Crizotinib. (C-D) Cytotoxicity assays of (C) LoVo and (D) LS180 cells treated with STAT3 inhibitor,
Cryptotanshinone. (E-F) Cytotoxicity assays of (E) LoVo and (F) LS180 cells treated with STAT3
inhibitor, Stattic. Cytotoxicity assays were performed after 4 days using CellTiter-Glo. (G) Table of
average IC50s for 2-3 different experiments performed in triplicate.
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To further elucidate the relationship of LGR5 expression and MET/STAT3 activation
on drug resistance, constitutively activate STAT3 (STAT3-CA) was overexpressed in both
LoVo and LS180 cells by transient transfection. Through western blot analysis, it was found
that STAT3-CA led to loss of LGR5 (Fig. 12A). Cytotoxicity assays also showed STAT3-CA
cells had increased resistance to irinotecan, supporting its role in drug resistance for LGR5CRC cells (Fig. 12B-C). We next tested if overexpression of LGR5 leads to decreased
MET/STAT3 activation. We selected to use HCT116 cells, a CRC cell line that does not
endogenously express LGR5 but has higher levels of activated MET/STAT3. LGR5 was
overexpressed by transient transfection using increasing amounts of DNA. We show gradual
loss of MET and STAT3 activation with increasing amounts of transfected LGR5 plasmids
(Fig. 12D). Using CellTiter-Glo assay, LGR5 overexpression was also found to sensitize
HCT116 cells to irinotecan treatment, decreasing IC50 by 5-fold (Fig. 12E). These findings
further support a role for MET/STAT3 signaling for driving drug resistance in LGR5- CRC
cells.
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Figure 12. Effects constitutively active STAT3 and LGR5 overexpression on irinotecan
resistance. (A) Western blot of LoVo and LS180 cells transiently transfected with Flag-tagged
constitutively active STAT3 (STAT3-CA) and effects on MET and STAT3 phosphorylation. (B-C)
Cytotoxicity assay of (B) LoVo and (C) LS180 cells transfected with vector or STAT3-CA and treated
with irinotecan for 4 days. (D) Western blot of HCT116 cells transiently transfected with increasing
amounts of LGR5 and effects on MET and STAT3 phosphorylation. (E) Cytotoxicity assay of HCT116
cells transfected with vector or LGR5 and treated with irinotecan for 4 days. HCT116 experiments were
performed with Ashlyn Parkhurst.
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3.8 MET/STAT3 inhibitors enhance efficacy of chemotherapy and ADCs in
vitro
To verify if MET/STAT3 activation is at least partially responsible for increased drug
resistance, we first compared combination treatment of STAT3 or MET inhibitors with
irinotecan. In LoVo cells we found that both the MET inhibitor, crizotinib, and the STAT3
inhibitor, stattic, synergized with irinotecan to increase efficacy (Figs.13A-B). The effect was
much greater in LGR5 KD cells, as they have increased levels of active MET and STAT3.
Combination treatment of MET and STAT3 inhibitors also synergized with irinotecan in
LS180 cells (Fig. 13C). We then tested if MET and STAT3 inhibitors would enhance
therapeutic efficacy of anti-LGR5-MMAE ADC treatment. As shown in Figs. 9D-E, both
inhibitors enhanced efficacy of ADC treatment in LoVo and LS180 cells, however the effect
was less in LoVo cells since they are already sensitive to anti-LGR5-MMAE ADCs. Together
with previous findings, we show combination therapy enhances efficacy of chemotherapy and
ADCs in CRC cells, potentially due to increased activation of MET/STAT3 signaling.
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Figure 13. MET and STAT3 inhibitors synergize with irinotecan and anti-LGR5 ADCs. (A-B)
Cytotoxicity assays of LoVo shCTL and shLGR5 cells treated with increasing concentrations of
irinotecan in combination with (A) 0.3 µM Crizotinib and (B) 0.3 µM Stattic. (C) LS180 cells treated
with irinotecan alone or in combination with 1 µM Crizotinib or Stattic. (D-E) Cytotoxicity assays of
(D) LoVo and (E) LS180 cells treated with increasing doses of anti-LGR5-MMAE ADC alone or in
combination with Crizotinib or Stattic as indicated. Experiments were performed 2-3 times in triplicate.
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3.9 Combination treatment of Irinotecan with STAT3 inhibitor enhances
anti-tumor efficacy and survival
To test the efficacy of combination treatment of irinotecan with a STAT3 inhibitor in
vivo, nu/nu mice were injected with 1.0-2.0 X106 LoVo or LS180 CRC cells. Once tumors
reached an average of approximately 100mm3 they were randomized into four groups. Mice
were treated with vehicle, 20 mg/kg irinotecan every 5 days, 10 mg/kg stattic every 2 days, or
combination treatment of irinotecan and stattic (Fig. 14). Treatment was terminated after the
first vehicle control tumor reached 2000mm3. In LoVo xenografts, each treatment resulted in
a significant decrease in tumor growth, with combination treatment having the most
pronounced effect (Fig. 14A). Similar effects were observed in LS180 xenografts (Fig. 14B).
However, stattic treatment alone did not result in a significant effect, likely due to the rapid
growth of LS180 cells compared to LoVo cells in vivo. Combination treatment in both CRC
models significantly enhanced efficacy in both models, with 82% and 64% inhibition in tumor
growth for LoVo and LS180 xenografts, respectively (Figs. 14A-B). Irinotecan treatment alone
only resulted in ~50-55% inhibition of tumor growth. We next monitored the effects on
survival after treatment was terminated and found that combination treatment increased
survival in both LoVo and LS180 xenograft models (Fig. 14C-D). No significant effect in body
weight nor overt toxicity was observed during treatment (Figs. 14E-F). These data provide
evidence of improved therapeutic efficacy in targeting STAT3 along with standard
chemotherapy.
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Figure 14. Combination treatment of Irinotecan with STAT3 inhibitor in vivo. (A) Tumor growth
curve of LoVo xenograft mice treated with vehicle (n=5), 10 mg/kg stattic (n=4), 20mg/kg irinotecan
(n=4), or combination (n=7). (B) Tumor growth curve of LS180 xenograft mice treated with vehicle
(n=8), 10 mg/kg stattic (n=6), 20mg/kg irinotecan (n=7), or combination (n=6). Statistical analysis was
performed using one-way ANOVA and Dunnett’s multiple comparison test. *, P ≤ 0.05, **, P ≤ 0.01,
***, P ≤ 0.001 compared to vehicle unless otherwise indicated. (C-D) Kaplan−Meier survival plot for
(C) LoVo and (D) LS180 xenografts days post-treatment initiation. (E) Average body weight mice over
the course of the study. Error bars are SD.
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Chapter 4: Discussion
While LGR5+ cells have been consistently confirmed as a tumor initiating CSCs, able
to regenerate all cancer cell type needed for proliferative growth, the actual role of LGR5 in
plasticity, drug resistance, and metastasis has been of recent interest. Through LGR5 gene
knockdown and overexpression studies, LGR5 expression has been linked to both tumor
suppression and pro-oncogenic effects in CRC122. In this study, we showed that therapeutic
treatment with standard chemotherapies, irinotecan and 5-FU, in CRC cells induces loss of
LGR5 expression (Fig. 5A-C). Loss of LGR5 is due to gradual decrease in expression and not
selection against LGR5+ vs LGR5- cells as the CRC cell lines are rather homogenous for
LGR5 expression (Fig. 5C). Previously, we published that LGR5KD and LGR5KO cells have
increased drug resistance to both 5-FU and irinotecan compared to their respective LGR5+
control cell lines93. These findings are consistent with prior reports showing both
chemotherapy and radiotherapy initiate a switch from an LGR5+ state to a more drug resistant
LGR5- state91,92.
As previously mentioned, our lab generated an anti-LGR5-MMAE ADC by
conjugating the antimitotic, tubulin-inhibiting agent monomethyl auristatin E (MMAE) by a
cleavable chemical linker57. While targeting LGR5 resulted in cancer cell death in vitro and
inhibited tumor growth and recurrence in vivo, once treatment was ceased, tumors re-emerged
in some of the mice57. This suggested that tumor re-emergence was potentially due to the
presence of LGR5- cancer cells which may have converted back to LGR5+ CSCs for tumor
proliferation, in a manner similar to other findings43,88,94. Here we show that chemotherapy or
ADC treatment in CRC cells induce loss of LGR5 expression (Fig. 5B-D); we further
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confirmed that CRC cells indeed interconvert between LGR5+ and LGR5- states as removal
of treatment leads to the re-emergence of LGR5 expression (Fig. 5E).
In addition to increased drug resistance and proliferation, which we and others have
previously reported, we showed that loss of LGR5 in LoVo cells leads to increased
clonogenicity, migration, and invasion (Fig. 6). Similar findings have been reported by other
groups using different CRC cell lines74,123 and relates to previous findings that showed the
invasive front of CRCs consist of LGR5- cells and the majority of circulating cancer cells and
seeding cells which are primarily LGR5- 94,124. These findings support the notion that the loss
of LGR5 expression may drive disease resistance and relapse after treatment and may also play
an important role in the progression of CRC to metastasis. However, while these cells are
capable of sustaining the tumor, the re-emergence of LGR5 expression is still necessary for
rapid tumor growth, possibly to generate a more favorable microenvironment for growth125.
Because of the increased tumorigenicity and drug resistance of LGR5KD cells, we
wanted to identify signaling mechanisms which are mediating these phenotypic changes.
Based on recent findings, mechanistically, LGR5 binds to an RSPO ligand to potentiate Wnt/βcatenin signaling68. However, in both normal and cancer cells loss of LGR5 expression led to
increased activation and nuclear accumulation of β-catenin (Figs. 7A-B), and an increase in
levels of markers related to activated Wnt/β-catenin signaling. This observation suggests that
LGR5 may play a role in the negative regulation of Wnt signaling and as LGR5 is a
transcriptional target gene of Wnt, it may act in a self-regulation manner 49,73,75. Along with βcatenin activation, STAT3 and its upstream mediator JAK were found to have increased
activation in LGR5KD LoVo cells (Fig. 7A). We also observed increased nuclear localization
of STAT3, indicating increased transcriptional activation (Fig. 7B). This was further confirmed
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through an observed an increased expression of Bcl-xL and Cyclin D1, which are
transcriptional targets of STAT3 which promote cell survival, and drug resistance.
Consistently, BIM, which directly antagonizes Bcl-xL was decreased in LGR5KD cells (Fig.
7C)121,126,127. We also showed that loss of LGR5 expression in DLD-1 and LS180 cells also
resulted in increased STAT3 phosphorylation (Figs. 9B-C). These findings indicate that
LGR5KD/KO cells may rely on STAT3 signaling for driving drug resistance and the metastatic
phenotype.
Crosstalk and interactions between STAT3 and the Wnt/β-catenin signaling pathways
has been previously reported128,129,130,131. However, LGR5KD CRC cells treated with
XAV939, a small molecule inhibitor that enhances β-catenin degradation through stabilization
of Axin2 a component of the destruction complex, did not dampen activation of STAT3 (Fig.
8D)132,133. These findings suggest that enhanced Wnt activation is likely not responsible for
STAT3 activation; at least in LoVo cells. In fact, in findings by Ibraham et.al., show that βcatenin may be a transcriptional target for STAT3, leading to its upregulation134. Furthermore,
suppression of STAT3 through targeted inhibition has been shown to prevent Wnt signaling
activation131. However, since we observed nuclear accumulation of both STAT3 and β-catenin
in LGR5KD cells (Fig. 7C), it is possible that they may interact to promote transcriptional
activity.
As STAT3 signaling has been shown to be mediated through IL6R/Gp130, EGFR and
MET97,135, we investigated which possible upstream mediator may activate STAT3 in response
to loss of LGR5. Since our CRC cell lines did not express IL6R and the Gp130 inhibitor SC144
failed to inhibit STAT3 activation in our LGR5KD cells (Fig. 8A), these findings suggest that
increased STAT3 activation was not mediated by the IL-6R/Gp130 pathway. EGFR is an
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important therapeutic target in CRC which has also been linked to activation of the JAKSTAT3 signaling pathway in CSCs and is believed to be responsible for maintaining CSC
survival104,136. However, no significant increase in EGFR activation was observed in LGR5KD
cells and treatment with EGFR inhibitor gefitinib failed to ablate STAT3 activation (Figure
8B-C). Together, these findings reveal that neither EGFR nor IL-6R/Gp130 were responsible
for mediating STAT3 activation in LGR5KD CRC cells.
Overexpression of MET has been shown to play a critical role in progression and
invasion in CRC, correlating with tumor staging and lymph/liver metastasis, making it a
promising target in late-stage CRC treatment107–109. MET mutations are rarely found in patients
with CRC (2-5%), however overexpression of HGF/MET was observed in 50-70% of
CRCs108,110. This has been attributed to amplification of HGF-MET through either paracrine
or autocrine loops as MET activation has been shown to enhance HGF transcriptional
activation137. MET is also known to play a vital role in cell survival and acquired drug
resistance through JAK-STAT3 signaling activation in CRC98. Interestingly, increased MET
phosphorylation was observed in our LGR5KD/KO cells along with increased levels in the
cytoplasm and nucleus (Figs. 9A-D). Increased MET/STAT3 activation was also detected in
CRC cells with corresponding loss of LGR5 expression in response to either chemotherapeutic
treatment or targeted LGR5 ADC treatment (Figure 10A-D), suggesting that MET/STAT3
activation plays a role in therapy induced CRC plasticity. Consistently, LGR5 overexpression
in the LGR5- HCT116 CRC cell line resulted in decreased MET/STAT3 activation and
increased irinotecan sensitivity, whereas constitutively active STAT3 led to downregulation of
LGR5 expression along with enhanced drug resistance (Fig. 12). When treating our LGR5KD
cells with the MET inhibitor, crizotinib, we observed loss of phosphorylated STAT3 (Fig. 9E).
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These observations suggest that STAT3 activation with LGR5KD/KO is mediated by MET
activation. This is significant as MET mediated activation of STAT3 has been implicated in
EGFR and IL-6 targeted therapeutic resistance in CRC138–140. Another recent report showed
enhanced MET/STAT3 signaling mediated resistance to MEK inhibitors in KRAS mutant
CRC Cancer58,141,142. In our study, to test the potential effects of STAT3 inhibition on MET
activation, we used stattic, a non-peptidic small molecule which inhibits STAT3 dimerization,
and cryptotanshinone, a cell-permeable diterpenoid anthraquinone originally derived from
Salvia miltiorrhiza which inhibits signaling of the JAK-STAT3 pathway143–145. Inhibition of
STAT3 with either stattic or cryptotanshinone in LGR5KD cells led to loss of MET
phosphorylation (Figs. 9E), indicating the existence of a possible positive feedback loop where
MET phosphorylates STAT3, and in turn, STAT3 potentiates MET activation. It is currently
unclear how STAT3 activation leads to activation of MET, but one study has posited that MET
activated STAT3 enhances HGF transcriptional activity146.
We demonstrated that MET or STAT3 inhibition synergized with irinotecan and antiLGR5 ADCs in vitro (Fig. 13). LGR5KD/KO cells were more sensitive to STAT3 and MET
inhibitors compared to their LGR5+ counterparts (Figs. 11A-G and Figs. 13A-B), indicating
that LGR5- cells are more dependent on MET/STAT3 signaling for survival and integral for
their enhanced drug resistance. Combination treatment of STAT3 inhibitor, stattic, with
irinotecan enhanced therapeutic efficacy and survival in CRC xenograft models. Though
STAT3 inhibitors have shown poor clinical efficacy and/or toxicity147, several more STAT3
inhibitors are currently in development which appear more promising148–150. These findings
indicate that STAT3 or MET-targeted agents may be highly effective when used in conjunction
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with irinotecan or LGR5-targeted ADCs to treat CRC. Further in vivo studies of these
combination therapies need to be further tested.
As mentioned previously, LGR5 plays a role in the dephosphorylation of IQGAP1, thus
loss of LGR5 leads to accumulation of phosphorylated IQGAP173. Importantly, IQGAP1 is
phosphorylated at tyrosine sites by MET and shown to play an integral role in HGF induced
MET activation78,143. This was demonstrated in a study which showed that inhibition of MET
by crizotinib resulted in decreased phosphorylation of IQGAP1 and loss of IQGAP1 ablated
HGF expression leading to MET deactivation77. Thus, we postulate that accumulation of
phosphorylated IQGAP1 may be what is initiating the MET-STAT3 signaling activation and
the positive feedback loop (Figure 12A-C). For instance, in LGR5- CRC, phosphorylated
IQGAP1 may preferentially bind to the tyrosine kinase terminal on MET and increase colocalized kinase activation, or block activation and interaction of a phosphatase, such as SHP2. SHP-2 is associated with the dephosphorylation of STAT3, inactivating its function151,152.
As IQGAP1 also has been shown to shown to shuttle signaling transducer to the nucleus to
potentiate activation, it may also play this role in localizing STAT3 to the perinuclear region
promoting its translocation to the nucleus after it is activated by MET79. We propose a model
which depicts LGR5 playing an antagonistic role in MET-STAT3 activation through its
dephosphorylation of IQGAP1. This model sheds some light as to why loss of LGR5 leads to
a more metastatic phenotype and why the majority of circulating tumor cells which seed
metastases are LGR5-, as increased phosphorylation of IQGAP1 leads to decreased cell-to-cell
adhesion promoting cell release from the primary tumor. This work concomitantly with
activation of MET-STAT3 which leads to increased invasion and drug resistance. However,
this proposed mechanism requires further investigation73,109,124.
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Figure 15: Proposed MET-IQGAP1-STAT3 Model. With loss of LGR5, phosphorylated
IQGAP1 accumulates and may promote MET-STAT3 signaling by 1.) increasing kinase
interaction with the intracellular MET-domain77, 2.) IQGAP1 inhibiting SHP-2, a phosphatase
which inhibits STAT3151,152, 3) IQGAP1 acts as a shuttle to promote nuclear localization of
STAT379, to promote transcription of target genes (i.e. HGF). (Created with BioRender.com)
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CHAPTER 5: FUTURE DIRECTIONS
Going forward, our lab will be further exploring the relationship between LGR5IQGAP1 and MET-STAT3 using other CRC cell lines and tumor organoids. We will perform
co-immunoprecipitation and ICC and confocal analysis to detect changes in protein-protein
interactions and localization in control vs. LGR5KD/KO cells. We will also identify new
protein modulators that may be playing a role in this mechanism to drive plasticity and drug
resistance. We will also continue in vivo experiments by testing in other STAT3 and MET
inhibitors in combination with irinotecan or our anti-LGR5-targeted ADCs. Altogether, these
proposed combination therapies may be an improved approach to overcome drug resistance
and plasticity to eradicate CRC.
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